A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system

• Auteurs principaux: Mingdi Liu (Auteur), Liting Gu (Auteur), Yuning Zhang (Auteur), Honglan Zhou (Auteur), Yishu Wang (Auteur), Zhi-Xiang Xu (Auteur)
• Format: Livre
• Publié: Frontiers Media S.A., 2024-01-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Background: Mesalazine, a preparation of 5-aminosalicylic acid, is a medication widely used in clinical practice as a first-line therapy in the treatment of mild and moderate inflammatory bowel disease. However, the long-term safety of mesalazine in large sample population was unknown. The current s...